URACYL AND THYMINE DERIVATIVES FOR TREATING HEPATITIS C Russian patent published in 2015 - IPC C07D239/22 C07D239/54 C07D401/10 C07D403/10 C07D409/10 C07D413/10 C07D417/10 A61K31/513 A61P31/12 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which possess the properties of HCV polymerase inhibitors. In formula , is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; R¹ and R³ are specified in hydrogen and methyl; R² represents hydrogen; R⁵ is specified in a group consisting of hydrogen, hydroxy, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆alkoxy, C₂-C₆alkenyloxy, C₃-C₆alkynyloxy and halo; L represents a bond, and R⁶ represents a condensed 2-ring carbocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of R^E, R^F, R^G, R^H, R^I, R^J and R^K; or L is specified in a group consisting of a bond, C≡C, C(O)N(R^C), N(R^D)C(O), C₁-C₂-alkylene, C(H)₂O, OC(H)₂, cyclopropyl-1,2-ene, C(H)₂N(R^L), N(R^M)C(H)₂, C(O)CH₂ and CH₂C(O), and R⁶ is specified in a group consisting of C₅-C₆-carbocyclyk and 5-6-merous heterocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L and R^M; the R⁴, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L and R^M values are presented in the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing the above compounds, to using the compounds for producing a drug preparation for HCV RNA polymerase inhibition and hepatitis C treatment, and to a method for preparing the above compounds.

21 cl, 46 dwg, 42 tbl, 140 ex